C4 Therapeutics, Inc.
CCCC · NASDAQ
Market closed$3.69$0.110000 (+3.07%)After hours $3.72 · +0.81%
Key statistics
Previous close$3.58
Open$3.48
Day high$3.77
Day low$3.44
52-week high$5.17
52-week low$1.69
Market cap305.63M
Volume2.45M
Average volume3.18M
P/E ratio-3.10
Forward P/E—
EPS-1.19
Dividend yield0.00%
Market context
Why it moved
CCCC's shares rose following increased unusual options activity flagged in market reports and positive developments highlighting CCCC's growing role as a key infrastructure partner in strategic international projects, boosting investor sentiment.
What is happening
Recent company-specific developments and publisher coverage.
Investing News Network · June 11, 2026C4 Therapeutics Presents Phase 1 Data at European Hematology Association 2026 Congress Highlighting Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader for Multiple Myeloma in Heavily Pretreated Relapsed/Refractory PopulationInvesting News Network · May 12, 2026C4 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business HighlightsReuters · April 10, 2026C4 Therapeutics, Roche expand partnership with new cancer deal worth over $1 billionStock Titan · April 9, 2026Roche expands C4T deal on a new cancer-drug approach worth $1B-plusClinical Trials Arena · March 26, 2026C4 Therapeutics begins dosing in Phase Ib trial for multiple myelomaPluang · March 25, 2026C4 Therapeutics doses first patient in Phase 1b trial combining cemsidomide with elranatamab for multiple myelomaClinical Trials Arena · February 24, 2026C4 Therapeutics doses first patient in MOMENTUM trial for multiple myeloma Mt Newswire · June 11, 2026C4 Therapeutics Reports 53% Response Rate for Cemsidomide at RP2D Benzinga · June 11, 2026C4 Therapeutics To Present Further Analysis From Fully Enrolled Phase 1 Trial Of Cemsidomide In Combination With Dexamethasone For Treatment Of RRMM At EHA 2026 Congress Benzinga · June 1, 2026Evercore ISI Group Maintains Outperform on C4 Therapeutics, Raises Price Target to $12 Benzinga · May 12, 2026C4 Therapeutics Q1 EPS $(0.20) Beats $(0.27) Estimate, Sales $6.152M Beat $3.333M Estimate Benzinga · April 9, 2026C4 Therapeutics Deepens Roche Alliance To Target Breakthrough Cancer Therapies Mt Newswire · April 9, 2026C4 Therapeutics Expands Roche Partnership to Develop Degrader-Antibody Conjugates Against Cancer Benzinga · April 9, 2026C4 Therapeutics Teams Up With Roche On New Cancer Drug Approach, Secures $20M Upfront, Eyes Over $1B In Future Milestones Mt Newswire · March 25, 2026C4 Therapeutics Doses First Patient in Phase 1b Trial of Multiple Myeloma Combination Treatment